Top Industry Leaders in the Overactive Bladder Treatment Market
Latest Overactive Bladder Treatment Companies Updates:
Astellas Pharma expands indications for Myrbetriq® (mirabegron) to include treatment of overactive bladder (OAB) with urge urinary incontinence (UUI) in men in the US: This approval broadens the reach of this popular medication, benefiting more OAB patients.
Medtronic unveils a new neuromodulation therapy system for OAB, the InterStim™ Micro neurostimulator: This smaller, implantable device offers a less invasive option for patients seeking long-term relief from OAB symptoms.
Urovant Sciences receives FDA approval for Géneresse® (vibegron extended-release tablets) for the treatment of OAB in adults: This new generic drug expands treatment options and potentially contributes to cost reduction for patients.
Botox® continues to dominate the neuromodulation segment: Allergan's botulinum toxin A injections remain a well-established option for OAB treatment, despite increasing competition from newer technologies.
List of Overactive Bladder Treatment Key companies in the market:
- Astellas Pharma Inc.
- Pfizer Inc.
- Teva Pharmaceutical
- Allergan Plc.
- Mylan N.V.
- Endo International Plc
- Hisamitsu Pharmaceutical Co. Inc.
- Sanofi S. A.
- Aurobindo Pharma Limited
- Johnson & Johnson"
